Keyphrases
5-fluorouracil (5-FU)
16%
Acetylcholinesterase
16%
Advance Breast Cancer
16%
Anthracyclines
48%
Breast
8%
Breast Cancer
38%
Breast Cancer Patients
51%
Chemotherapy
10%
Clinical Outcomes
16%
Clinical Response
64%
Cyclophosphamide
17%
Diagnostic Tool
16%
Doxorubicin
17%
Factor Level
16%
Fast Diagnosis
8%
General Hospital
48%
Hirschsprung Disease
16%
Histological Subtypes
5%
Immunosensor
8%
Indonesia
22%
Interleukin-6
16%
Locally Advanced Breast Cancer
50%
Lymphocyte Count
16%
Mastectomy
8%
Metastasis
24%
Metastatic Breast Cancer
20%
Microfluidic Immunosensor
16%
Microfluidic System
16%
Negative Reactivity
5%
Neoadjuvant Chemotherapy
64%
Neutrophil-lymphocyte Ratio
32%
Neutrophil-to-lymphocyte Ratio
32%
Operative
16%
Patient Characteristics
16%
Patient Profile
16%
Point-of-care
8%
Port of Entry
6%
Postmastectomy
16%
Predictive Factors
17%
Recent Applications
16%
Self-image
16%
Self-improvement
16%
Serum Levels
17%
Significant Relationship
8%
Surabaya
14%
Tetanus
16%
Tumor Necrosis Factor-α
32%
Tumor Size
6%
Women with Breast Cancer
16%
Young Breast Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylcholinesterase
16%
Anthracycline
48%
Biological Marker
7%
Breast Cancer
100%
Chemotherapy
64%
Cyclophosphamide
17%
Doxorubicin
17%
Fluorouracil
17%
Hirschsprung's Disease
16%
Interleukin 6
16%
Metastatic Breast Cancer
18%
Neoplasm
6%
Tetanus
16%
Tumor Necrosis Factor
32%
Nursing and Health Professions
Anthracycline
48%
Blood Level
16%
Breast Cancer
84%
General Hospital
27%
Interleukin 6
16%
Mastectomy
16%
Metastatic Breast Cancer
18%
Neoadjuvant Chemotherapy
48%
Neutrophil Lymphocyte Ratio
32%
Tumor Necrosis Factor
32%
Tumor Volume
5%